Shanghai, China
Gracell Biotechnologies, a prominent player within the biopharmaceutical sector, stands as a global clinical-stage company under the esteemed umbrella of the AstraZeneca Group. Founded in 2017 and headquartered in China, Gracell is at the forefront of pioneering cutting-edge solutions for cancer and autoimmune diseases through its innovative cell therapy approaches.
The company distinguishes itself with proprietary technologies such as FasTCAR and TruUCAR, along with its SMART CART™ technology modules. These platforms aim to overcome the limitations of traditional CAR-T therapies by reducing manufacturing time, enhancing T cell quality, and expanding effectiveness in solid tumors and autoimmune conditions.
In a notable development, Gracell Biotechnologies received a substantial $1.00 billion acquisition investment from AstraZeneca in December 2023, marking a significant step in its journey to redefine cancer and autoimmune disease treatment.
